Senior Editor, Diagnostic Imaging
Study: PET/CT Multivariate Model Enhances Accuracy for Diagnosing Prostate Cancer
September 13th 2023For men with PSA scores between 4 to 10 ng/mL, a multivariate prediction model that incorporates 68Ga-PSMA PET/CT had a 92.7 AUC for predicting clinically significant prostate cancer, according to newly published research.
FDA Clears AI Software for CT Detection and Triage of Obstructive Hydrocephalus
September 13th 2023Indicated for the triage and notification of obstructive hydrocephalus on non-contrast brain computed tomography (CT), the artificial intelligence (AI)-enabled software is reportedly the first radiology triage modality to obtain the Food and Drug Administration’s (FDA) Breakthrough Device Designation.
Large Mammography Study Suggests AI is Equivalent to Radiologists for Double Reading of Exams
September 11th 2023In a prospective study of over 55,000 women who had screening mammography, researchers found that double-reading by a radiologist and artificial intelligence (AI) was non-inferior to double-reading by two radiologists in detecting breast cancer.
Philips Unveils New Contrast-Enhanced Ultrasound Application for EPIQ Elite Device
September 8th 2023The Microvascular Imaging Super Resolution Contrast-Enhanced Ultrasound application reportedly leverages micro-bubble contrast media to provide enhanced spatial resolution for imaging of malignant lesions.
Study: 'All Men with PSAs Between 3 and 20 ng/mL Should Undergo MRI Before Biopsy'
September 7th 2023In a study of over 23,000 men who had PSA testing, researchers found that the adoption of pre-biopsy MRI resulted in a 21 percent decrease in negative biopsies and a 37 percent increase in the proportion of diagnosed Gleason score 7 to 10 prostate cancers.
Emerging PSMA PET Agent May Offer Improved Detection of Prostate Cancer
September 7th 2023The PSMA PET agent 64Cu SAR-bisPSMA detected a higher number of prostate cancer lesions and had a significantly higher SUVmax and SUVmean than 68Ga PSMA-11 PET/CT, according to initial data from a prospective multisite study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Can AI Match Radiologist Assessment of Screening Mammography Exams?
September 5th 2023In separate test sets that included challenging mammography cases, researchers found that artificial intelligence (AI) demonstrated similar sensitivity and specificity for detecting breast cancer in comparison to assessments from over 500 clinicians.
Study: 66 Percent of Men with Positive MRI for Prostate Cancer Had Normal PSA Levels
August 23rd 2023Two-thirds of men with a positive screening MRI for prostate cancer had PSA levels below 3 ng/mL and 91 percent of these men had clinically significant prostate cancer, according to newly published research.
New Research Shows Consequences of Delayed Diagnosis in Mammography Screening
August 22nd 2023Primary diagnostic delays in mammography screening led to a greater than 10 percent higher incidence of lymph node metastasis with invasive breast cancer in comparison to women without a primary diagnostic delay, according to new research out of the Netherlands.
Emerging Innovations in Molecular Imaging
August 21st 2023In interviews at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers discussed the potential impact of ultra-high resolution brain positron emission tomography (PET) as well as emerging PET radiotracers for detecting coronary artery disease in obese patients and diagnosing clear cell renal cell carcinoma.
Is Pre-Imaging Biopsy Necessary for Prostate Cancer Staging in Elderly Patients?
August 17th 2023For patients 80 years of age or older that have a PSA level at 20 ng/mL or higher, PSMA PET/CT has a high likelihood of success in diagnosing and staging prostate cancer regardless of pre-imaging biopsy use, according to newly published research.
Study Reveals Tradeoffs Between Contrast-Enhanced Mammography and MRI for Supplemental Screening
August 16th 2023In a new study comparing standard breast MRI, abbreviated breast MRI and contrast-enhanced mammography in supplemental breast cancer screening, researchers found that MRI offered a greater than 14 percent higher cancer detection rate and a nearly 39 percent higher sensitivity rate than CEM.
Viz.ai Gets FDA Nod for Hypertrophic Cardiomyopathy Module
August 16th 2023The De Novo approval for Viz HCM, which assesses electrocardiograms with artificial intelligence (AI) to identify possible cases of hypertrophic cardiomyopathy (HCM), is the 12th FDA clearance of algorithms on the Viz.ai Platform.